BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Emavusertib readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Emavusertib\, from ClinicalTrials.gov est
 imates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06696768-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20261231
DTEND;VALUE=DATE:20270101
SUMMARY:Emavusertib: Phase 1 readout est. (NCT06696768)
DESCRIPTION:Emavusertib\, phase 1.\nStudy: Clinical Trial of an Anti-cancer
  Drug\, CA-4948 (Emavusertib)\, in Combination With Chemotherapy Treatment
  (FOLFOX Plus Bevacizumab) in Metastatic Colorectal Cancer\nEstimated prim
 ary completion: 31 December 2026. This is a ClinicalTrials.gov estimate\, 
 not a confirmed readout date\, and it can move.\nDrug page: https://assetm
 emo.bio/drug/emavusertib#upcoming-events\nRegistry record: https://clinica
 ltrials.gov/study/NCT06696768
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06439836-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20270601
DTEND;VALUE=DATE:20270602
SUMMARY:Emavusertib: Phase 1 readout est. (NCT06439836)
DESCRIPTION:Emavusertib\, phase 1.\nStudy: Pembrolizumab Plus CA-4948 for t
 he Treatment of Patients With Progressive Metastatic Urothelial Cancer Des
 pite Prior Immunotherapy\nEstimated primary completion: 1 June 2027. This 
 is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it c
 an move.\nDrug page: https://assetmemo.bio/drug/emavusertib#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06439836
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT03328078-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:Emavusertib: Phase 1/2 readout est. (NCT03328078)
DESCRIPTION:Emavusertib\, phase 1/2\, Primary Central Nervous System Lympho
 ma.\nStudy: CA-4948-101: Open-Label\, Dose Escalation and Expansion Trial 
 of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous
  System Lymphoma (R/R PCNSL)\nEstimated primary completion: July 2027. Thi
 s is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it
  can move.\nDrug page: https://assetmemo.bio/drug/emavusertib#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT03328078
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07271667-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20271130
DTEND;VALUE=DATE:20271201
SUMMARY:Emavusertib: Phase 2 readout est. (NCT07271667)
DESCRIPTION:Emavusertib\, phase 2.\nStudy: A Study of Emavusertib + An Appr
 oved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic 
 Lymphocytic Leukemia (CLL) and Other B-cell Malignancies\nEstimated primar
 y completion: November 2027. This is a ClinicalTrials.gov estimate\, not a
  confirmed readout date\, and it can move.\nDrug page: https://assetmemo.b
 io/drug/emavusertib#upcoming-events\nRegistry record: https://clinicaltria
 ls.gov/study/NCT07271667
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07463820-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:Emavusertib: Phase 2 readout est. (NCT07463820)
DESCRIPTION:Emavusertib\, phase 2.\nStudy: A Trial Comparing Three Differen
 t Treatment Options for Adults With Low-Risk Myelodysplasia and Anemia (A 
 MyeloMATCH Treatment Trial)\nEstimated primary completion: 31 December 202
 7. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, 
 and it can move.\nDrug page: https://assetmemo.bio/drug/emavusertib#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT07463820
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05187182-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20280731
DTEND;VALUE=DATE:20280801
SUMMARY:Emavusertib: Phase 1 readout est. (NCT05187182)
DESCRIPTION:Emavusertib\, phase 1.\nStudy: CA-4948 in Combination With FOLF
 OX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and E
 sophageal Cancer\nEstimated primary completion: 31 July 2028. This is a Cl
 inicalTrials.gov estimate\, not a confirmed readout date\, and it can move
 .\nDrug page: https://assetmemo.bio/drug/emavusertib#upcoming-events\nRegi
 stry record: https://clinicaltrials.gov/study/NCT05187182
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05564390-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20290515
DTEND;VALUE=DATE:20290516
SUMMARY:Emavusertib: Phase 2 readout est. (NCT05564390)
DESCRIPTION:Emavusertib\, phase 2\, Acute Myeloid Leukemia.\nStudy: MYELOMA
 TCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment
  Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screeni
 ng Trial)\nEstimated primary completion: 15 May 2029. This is a ClinicalTr
 ials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug 
 page: https://assetmemo.bio/drug/emavusertib#upcoming-events\nRegistry rec
 ord: https://clinicaltrials.gov/study/NCT05564390
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07107750-2947@assetmemo.bio
DTSTAMP:20261121T005817Z
DTSTART;VALUE=DATE:20300630
DTEND;VALUE=DATE:20300701
SUMMARY:Emavusertib: Phase 1 readout est. (NCT07107750)
DESCRIPTION:Emavusertib\, phase 1.\nStudy: Emavusertib (CA-4948) in Combina
 tion With Cisplatin\, Gemcitabine\, and Durvalumab in Patients With Untrea
 ted Advanced or Metastatic Biliary Tract Cancer\nEstimated primary complet
 ion: 30 June 2030. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/em
 avusertib#upcoming-events\nRegistry record: https://clinicaltrials.gov/stu
 dy/NCT07107750
URL:https://assetmemo.bio/drug/emavusertib#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
